Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 853 posts found.

merck-keytruda-pembrolizumab-melanoma

NICE gives initial ‘no’ to NHS England for kidney cancer drug

February 18, 2020
Manufacturing and Production NHS England, NICE, clinical trials, inlyta, keytruda

The National Institute for Health and Care Excellence (NICE) has not recommended Keytruda (pembrolizumab) and Inlyta (axitinib) for the treatment …

News
4829288798_876971e5d4_b

Experts call on NICE to recommended a ban on OTC codeine sales

February 17, 2020
Research and Development, Sales and Marketing Codein, NICE, opioid crisis, opioids, prescription drugs

Experts have called for a ban on the sale of over the counter codeine as NICE is set to publish …

News
190509-f-jf989-059

NICE does not recommend cancer drug combination to the NHS

February 13, 2020
Business Services Cancer, Kidney cancer, NHS, NICE, keytruda, kidney disease

NICE has published draft guidance that does not recommend a new drug combination to combat untreated advanced renal cell carcinoma …

News
homeless-charity-poor-indifference

New report finds that health inequality in the UK greater than previously thought

February 12, 2020
Research and Development NHS, NICE, type 2 diabetes

Men are living seven years in poor health while women are living nearly ten years, according to a new report. …

News

NICE plans to use broader range of data in guidance

February 5, 2020
Research and Development NHS, NHS NICE, NICE

The British National Institute for Care Excellence has said it plans to use a broader range of data and analytics …

News
top_10_image_2

Top Ten most popular articles on Pharmafile.com this week

January 31, 2020
Medical Communications Janseen, Ketamine, NHS, NICE, Nasal sprays, Nasl, Top 10 of the week, top 10

This week nasal sprays based on illegal recreational drugs feature prominently, as the FDA has moved to approve Lannett Company’s …

News
janssen_latest_logo_on_sign

NICE rejects Janssen’s esketamine nasal spray Spravato for treatment-resistant depression

January 28, 2020
Manufacturing and Production, Sales and Marketing Janssen, NHS, NICE, Spravato, depression

Janssen’s Spravato (esketamine) nasal spray, derived from the party drug ketamine, has been turned down by NICE for NHS use …

News

NICE refuses Novo Nordisk’s obesity therapy Saxenda for NHS use

January 27, 2020
Sales and Marketing NHS, NICE, Novo Nordisk, UK, obesity, saxenda

NICE, the drug watchdog for England and Wales, has revealed that it has chosen not to recommend Novo Nordisk’s Saxenda …

News

NICE declines to recommend Astellas’ Xospata in rlapsed/refractory FLT3+ acute myeloid leukaemia

January 23, 2020
Sales and Marketing Astellas, NHS, NICE, UK, Xospata, acute myeloid leukaemia

The latest in a series of rejections over the past week, NICE has revealed that it has knocked back the …

News

No NICE recommendation for AstraZeneca’s Tagrisso in EGFR+ lung cancer

January 22, 2020
Research and Development, Sales and Marketing AstraZeneca, NICE, Tagrisso, pharma

AstraZeneca’s Tagrisso (osimertinib) has been knocked back for routine use on the NHS in England and Wales by the drug …

News

Janssen’s ulcerative colitis medicine not recommended by NICE for use in adults

January 21, 2020
Manufacturing and Production IBS, Irrated Bowels, NHS, NICE, bowel, ulcerative colitis

NICE has published draft guidance which does not recommend Stelara (ustekinumab) for treating moderately to severely active ulcerative colitis in …

News

Novartis’ Mayzent granted license by the European Medicines Agency

January 21, 2020
Manufacturing and Production CNS, European Medicines Agency, NHS, NICE, Novartis

The European Medicines Agency (EMA) has granted a licence for the use of Mayzent (siponimod) in the treatment of certain …

News

NICE turns down Bayer’s tumour-agnostic therapy Vitrakvi over evidence concerns

January 20, 2020
Sales and Marketing Bayer, Cancer, NICE, Vitravki

UK drug watchdog NICE has turned down Bayer’s Vitrakvi (larotrectinib) as a tumour-agnostic treatment solution on the NHS after it …

News
lynparza

Lynparza tablets approved for NHS use in platinum-sensitive, BRCA-mutated ovarian, fallopian tube or peritoneal cancer

January 16, 2020
Sales and Marketing AstraZeneca, MSD, NHS, NICE, UK, lynparza

It has been announced that tablet form of Lynparza (olaparib), the PARP inhibitor developed by AstraZeneca and MSD, has secured …

News

NICE shoots down Keytruda in head and neck cancer over data concerns

January 16, 2020
Sales and Marketing Cancer, NHS, NICE, UK, keytruda, pharma

It has been revealed that NICE has chosen to reject MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) for routine use on the …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023